News out...received site specific exemption to allow them to move forward.
Pharmagreen Receives Final Board Approval From Regional Government to Apply for the Development Permit for its Cannabis Biotech Tissue Culture Complex Project
Press Release | 10/01/2018
CARSON CITY, NV, Oct. 01, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - Pharmagreen Biotech, Inc. (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., received the following resolution which was passed by the Fraser Valley Regional District Board on September 25th meeting:
“THAT the Fraser Valley Regional District Board approve the proposed Site Specific Exemption to permit construction outside the Dewdney Dyke at 38482 Bell Rd be approved for a medical marijuana facility, as outlined in the Stirling Geoscience and Northwest Hydraulic Consultants geo-hazard reports dated May 15, 2018 and August 10, 2018”
Commenting on Pharmagreen Biotech’s progress, Peter Wojcik, President and CEO, stated, “We have completed a very significant milestone. This approval now allows us to move forward to permit application. We are now finalizing our design and engineering plans and look forward to starting our next stage which is land site preparation.”
About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.
WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: PHBI) company. WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally. Pharmagreens’ mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors. For further information on the company progress on the construction of a 63,000 square foot “Cannabis Biotech Complex” please visit www.pharmagreen.ca
